HER2-targeted therapy in breast cancer. Monoclonal antibodies and tyrosine kinase inhibitors
DL Nielsen, M Andersson, C Kamby - Cancer treatment reviews, 2009 - Elsevier
There is strong clinical evidence that trastuzumab, a monoclonal antibody targeting the
human epidermal growth factor receptor (HER) two tyrosine kinase receptor, is an important …
human epidermal growth factor receptor (HER) two tyrosine kinase receptor, is an important …
[HTML][HTML] Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer
MJ Piccart-Gebhart, M Procter… - … England Journal of …, 2005 - Mass Medical Soc
Background Trastuzumab, a recombinant monoclonal antibody against HER2, has clinical
activity in advanced breast cancer that overexpresses HER2. We investigated its efficacy …
activity in advanced breast cancer that overexpresses HER2. We investigated its efficacy …
Checkpoint inhibitors in breast cancer–current status
A Polk, IM Svane, M Andersson, D Nielsen - Cancer treatment reviews, 2018 - Elsevier
Introduction An increasing number of compounds directed against immune checkpoints are
currently under clinical development. In this review we summarize current research in breast …
currently under clinical development. In this review we summarize current research in breast …
Postoperative radiotherapy in high-risk postmenopausal breast-cancer patients given adjuvant tamoxifen: Danish Breast Cancer Cooperative Group DBCG 82c …
M Overgaard, MB Jensen, J Overgaard, PS Hansen… - The Lancet, 1999 - thelancet.com
Background Postmastectomy radiotherapy is associated with a lower locoregional
recurrence rate and improved disease-free and overall survival when combined with …
recurrence rate and improved disease-free and overall survival when combined with …
[HTML][HTML] Efficacy of HER2-targeted therapy in metastatic breast cancer. Monoclonal antibodies and tyrosine kinase inhibitors
DL Nielsen, I Kümler, JAE Palshof, M Andersson - The Breast, 2013 - Elsevier
Therapies targeting the human epidermal growth factor receptor (HER) 2 are effective in
metastatic breast cancer (MBC). We review the efficacy of HER2-directed therapies …
metastatic breast cancer (MBC). We review the efficacy of HER2-directed therapies …
Trastuzumab beyond progression in human epidermal growth factor receptor 2–positive advanced breast cancer: A German Breast Group 26/Breast International …
Purpose Trastuzumab shows clinical activity in human epidermal growth factor receptor 2
(HER-2)–positive early and advanced breast cancer. In the German Breast Group 26/Breast …
(HER-2)–positive early and advanced breast cancer. In the German Breast Group 26/Breast …
Second cancers among 40 576 testicular cancer patients: focus on long-term survivors
LB Travis, SD Fosså, SJ Schonfeld… - Journal of the …, 2005 - academic.oup.com
Background: Although second primary cancers are a leading cause of death among men
with testicular cancer, few studies have quantified risks among long-term survivors. Methods …
with testicular cancer, few studies have quantified risks among long-term survivors. Methods …
2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial
A Goldhirsch, RD Gelber, MJ Piccart-Gebhart… - The Lancet, 2013 - thelancet.com
Background Trastuzumab has established efficacy against breast cancer with
overexpression or amplification of the HER2 oncogene. The standard of care is 1 year of …
overexpression or amplification of the HER2 oncogene. The standard of care is 1 year of …
Breast cancer following radiotherapy and chemotherapy among young women with Hodgkin disease
LB Travis, DA Hill, GM Dores, M Gospodarowicz… - Jama, 2003 - jamanetwork.com
Context Second cancer is the leading cause of death in long-term survivors of Hodgkin
disease (HD), with exceptionally high risks of breast cancer among women treated at a …
disease (HD), with exceptionally high risks of breast cancer among women treated at a …
Lung cancer following chemotherapy and radiotherapy for Hodgkin's disease
LB Travis, M Gospodarowicz, RE Curtis… - Journal of the …, 2002 - academic.oup.com
Background: Lung cancer is a frequent cause of death in patients cured of Hodgkin's
disease, but the contributions of chemotherapy, radiotherapy, and smoking are not well …
disease, but the contributions of chemotherapy, radiotherapy, and smoking are not well …